Dr Antonio Gonzalez Martin speaks to ecancer about the primary analysis of the double-blind placebo-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial.

This trial evaluated atezolizumab with platinum-based chemotherapy (CT) and maintenance PARPi in late-relapsing recurrent ovarian cancer (rOC).

The primary endpoint of this trial was investigator-assessed progression-free survival.

The study found that combining atezolizumab with chemotherapy and maintenance niraparib for late-relapsing rOC did not significantly improve progression-free survival or overall response rate.